Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03665155 · ClinicalTrials.gov registry record · Phase 1
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03665155: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03665155 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03665155, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to test 89Zr-DFO-daratumumab, a new imaging agent, to demonstrate its safety and ability to take pictures of the myeloma.
Interventions
- OTHER Blood draws
- DRUG 89Zr-daratumumab
- DEVICE PET/CT scans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-09-05 |
| Est. Completion | 2020-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03665155
The ClinicalTrials.gov registry entry for NCT03665155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Blood draws is the first listed.
NCT03665155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03665155 about?
NCT03665155 is a clinical study titled "First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody". The purpose of this study is to test 89Zr-DFO-daratumumab, a new imaging agent, to demonstrate its safety and ability to take pictures of the myeloma.
What is the current status of trial NCT03665155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2018-09-05. Estimated completion is 2020-04-20.
What interventions are being tested in trial NCT03665155?
The interventions under investigation include: Blood draws (OTHER), 89Zr-daratumumab (DRUG), PET/CT scans (DEVICE).
Who is sponsoring clinical trial NCT03665155?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.